CJC-1295 and ipamorelin act on the growth hormone axis. This is a hormonal system regulated separately from testosterone. While there is a scientifically plausible reason to expect some interaction with sleep, no dedicated human trials have measured testosterone levels or detailed sleep outcomes in individuals using either compound. This article consolidates what is truly known on these subjects, briefly revisits claims about collagen and skin discussed in more detail elsewhere in this series, and then looks specifically at what a realistic hormonal activity timeline looks like in the first month.
Effect of CJC-1295 and Ipamorelin on Testosterone Levels
Growth hormone and testosterone are produced and regulated by two distinct hormonal control systems in the body. There is a growth hormone axis, which is acted upon by CJC-1295 and ipamorelin. And there is a separate hypothalamic-pituitary-gonadal axis, which manages testosterone production. No published human studies show either peptide directly raising testosterone. A review focused on growth hormone stimulators as a potential adjunctive therapy in men with low testosterone described how these compounds could support body composition and certain symptoms associated with low testosterone, as a supplement to standard testosterone therapy. However, this proposed benefit was framed as an indirect metabolic effect, not a direct hormonal increase. The review's authors were clear that supporting clinical data remain limited [1].
Separately, the basic pharmacological studies of ipamorelin are worth noting for a related reason. It has specifically been shown not to significantly raise cortisol or ACTH, unlike some older growth hormone-releasing peptides. This demonstrates true selectivity for the growth hormone pathway. However, the same study did not measure or report on testosterone at all [2].
Given the complete lack of direct evidence, it would be inaccurate to describe any peptide as a testosterone-boosting compound. Any link between these peptides and testosterone remains theoretical and unconfirmed by current research.
Effects of CJC-1295 and Ipamorelin on Sleep Quality
The proposed link between these peptides and sleep is based on a very well-established principle in general endocrinology. Growth hormone is naturally released in its largest pulses during deep, slow-wave sleep. This relationship has been documented for decades in sleep research. Since both CJC-1295 and ipamorelin are designed to amplify growth hormone release, this creates a scientifically plausible basis for expecting some interaction with sleep. This is likely the source of the common suggestion to dose these compounds before bedtime.
However, no controlled studies identified in the literature reviewed for this series directly measured sleep onset, sleep stage duration, or subjective sleep quality in individuals using any of the compounds. Claims of „sleep benefits” thus remain an extrapolation of general growth hormone and sleep physiology, rather than a confirmed finding specific to CJC-1295 or ipamorelin.
What is documented is the hormonal timing itself. CJC-1295 causes a sustained growth hormone increase lasting for six days or longer after a single dose, with the body's natural pulsatile rhythm preserved, not replaced [3], [4]. Ipamorelin causes a rapid, short pulse peaking around 40 minutes post-administration [5]. This timing information is an important background, but in itself does not establish an outcome regarding sleep quality.
Effects of CJC-1295 and Ipamorelin on Collagen and Skin
As discussed in more detail in an earlier article in this series, IGF-1—a hormone that increases as a result of CJC-1295 and ipamorelin's actions on growth hormone—has a real, documented role in stimulating collagen production. This has been demonstrated in laboratory studies of human skin fibroblasts, the cells responsible for building connective tissue [6]. These cell-level studies are warranted and scientifically sound. However, they mainly stem from studies using IGF-1 directly on cultured skin cells or topical tissue, rather than measuring actual skin or joint outcomes in humans where IGF-1 was systemically elevated through a growth hormone-stimulating peptide.
No studies identified in this research series measured skin thickness, wrinkle depth, or connective tissue outcomes in humans using CJC-1295 or ipamorelin. Therefore, while the underlying cellular mechanism is plausible, claims of visible skin or joint benefits from these peptides remain extrapolations rather than demonstrated clinical outcomes.
What to expect from CJC-1295 – first month effects
Based strictly on documented human hormonal kinetics, the first month of CJC-1295 use would be expected to unfold in a specific, trackable pattern. It is important to note that this describes changes in hormone levels as measured under clinical trial conditions, not subjective or physical effects an individual would necessarily notice day-to-day. In the primary human study, a single injection induced a surge in growth hormone within hours, lasting for six days or more. IGF-1, a more slowly rising, longer-lasting marker, took slightly longer to increase but then remained elevated for nine to eleven days after that single dose alone [3].
With repeated weekly or bi-weekly dosing, consistent with the compound's long half-life of approximately 5.8–8.1 days, studies have demonstrated that IGF-1 levels continue to rise and remain above baseline for up to 28 days. The study authors specifically noted evidence of a cumulative effect. This means that each subsequent dose built upon the elevated levels from the previous one, rather than simply repeating an isolated spike [3].
Translating this to a picture of the first month: the early days after the first dose would be expected, based on these hormonal data, to show a rising growth hormone curve, followed by a rising IGF-1 curve. A second, and possibly third, dose—if following a weekly or bi-weekly schedule similar to the study—would be needed to achieve a kind of sustained, cumulative rise in IGF-1 documented by day 28.
It's worth explicitly repeating that this schedule outlines blood hormone measurements from a specific clinical trial in healthy adults. It does not describe or predict when an individual might notice any physical changes, as no study tracked subjective or visible outcomes during the first month of use.
Limitations of current evidence
Regarding testosterone, sleep, and claims about collagen and skin, the same pattern holds true. Each connects to a real, well-documented general physiological principle. However, none of these have been directly tested in a dedicated human study for CJC-1295 or ipamorelin measuring that specific outcome.
The hormonal schedule for the first month is the most evidence-based section of this article. However, even it reflects data from blood tests from a controlled study, rather than a guide to subjective or visible effects.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. CJC-1295 and ipamorelin remain research compounds and are not approved by the FDA or European Medicines Agency for any medical use, whether used individually or in combination. No published human studies have directly measured testosterone levels, sleep quality, or skin outcomes in individuals using these compounds. The hormonal schedule described here reflects blood data from a specific clinical study and does not predict individual physical or subjective effects.
References
[1] Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: The role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl. 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
[2] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
[3] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[4] Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. https://doi.org/10.1210/jc.2006-1702
[5] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
[6] Hsieh, W.-J., Qiu, W.-Y., Percec, I., & Chang, T.-M. (2025). Insulin-like growth factor 1 (IGF-1) in hair regeneration: Mechanistic pathways and therapeutic potential. Current Issues in Molecular Biology, 47(9), Article 773. https://doi.org/10.3390/cimb47090773